• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    2/16/24 8:06:00 AM ET
    $AMN
    $AORT
    $CDIO
    $HCTI
    Professional Services
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
    Get the next $AMN alert in real time by email

    Gainers

    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday's pre-market session. The company's market cap stands at $1.5 million.
    • MediciNova (NASDAQ:MNOV) stock increased by 17.77% to $1.59. The market value of their outstanding shares is at $77.9 million. As per the press release, Q4 earnings came out yesterday.
    • Sarepta Therapeutics (NASDAQ:SRPT) shares moved upwards by 14.5% to $143.0. The market value of their outstanding shares is at $13.3 billion.
    • Ikena Oncology (NASDAQ:IKNA) shares rose 12.32% to $1.64. The company's market cap stands at $79.1 million.
    • Sientra (NASDAQ:SIEN) stock increased by 11.4% to $0.38. The company's market cap stands at $4.5 million.
    • Artivion (NYSE:AORT) stock increased by 10.86% to $20.0. The market value of their outstanding shares is at $820.9 million. As per the news, the Q4 earnings report came out yesterday.

    Losers

    • Inventiva (NASDAQ:IVA) shares decreased by 8.6% to $3.6 during Friday's pre-market session. The company's market cap stands at $185.9 million.
    • T2 Biosystems (NASDAQ:TTOO) shares declined by 7.67% to $5.9. The company's market cap stands at $23.8 million. As per the press release, Q4 earnings came out yesterday.
    • Healthcare Triangle (NASDAQ:HCTI) shares fell 7.66% to $2.51. The market value of their outstanding shares is at $10.8 million.
    • Hepion Pharmaceuticals (NASDAQ:HEPA) shares fell 7.41% to $2.5. The market value of their outstanding shares is at $10.8 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock decreased by 7.31% to $1.65. The company's market cap stands at $34.8 million.
    • AMN Healthcare Services (NYSE:AMN) shares fell 7.26% to $72.0. The market value of their outstanding shares is at $2.7 billion. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMN
    $AORT
    $CDIO
    $HCTI

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    Inventiva S.A.
    $IVA
    1/12/2026$12.00Outperform
    Leerink Partners
    Inventiva S.A.
    $IVA
    1/7/2026$12.00Buy
    UBS
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Inventiva S.A.
    $IVA
    11/6/2025$13.00Outperform
    Wolfe Research
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $AMN
    $AORT
    $CDIO
    $HCTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Information and Digital Hagan Mark Christopher converted options into 10,313 shares and covered exercise/tax liability with 4,139 shares, increasing direct ownership by 16% to 44,873 units (SEC Form 4)

    4/A - AMN HEALTHCARE SERVICES INC (0001142750) (Issuer)

    1/30/26 10:58:14 AM ET
    $AMN
    Professional Services
    Consumer Discretionary

    Amendment: CFO/COO Scott Brian M. converted options into 8,843 shares and covered exercise/tax liability with 3,592 shares, increasing direct ownership by 67% to 13,093 units (SEC Form 4)

    4/A - AMN HEALTHCARE SERVICES INC (0001142750) (Issuer)

    1/30/26 10:54:22 AM ET
    $AMN
    Professional Services
    Consumer Discretionary

    Amendment: Chief Legal Officer Laughlin Whitney M converted options into 4,488 shares and covered exercise/tax liability with 1,332 shares, increasing direct ownership by 15% to 23,652 units (SEC Form 4)

    4/A - AMN HEALTHCARE SERVICES INC (0001142750) (Issuer)

    1/30/26 10:51:47 AM ET
    $AMN
    Professional Services
    Consumer Discretionary

    $AMN
    $AORT
    $CDIO
    $HCTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

    - Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co., Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. Elevidys is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals wi

    2/24/26 9:07:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Mass. on Tuesday, March 3 at 1:50 p.m. E.T. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be ne

    2/24/26 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results

    Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(8%)Gross profit$195.1(11%)$774.1(16%)Net income (loss)($7.7)nm($95.7)nmDiluted earnings (loss) per share($0.20)nm($2.48)nmAdjusted diluted EPS*$0.22(70%)$1.36(59%)Adjusted EBITDA*$

    2/19/26 8:13:45 PM ET
    $AMN
    Professional Services
    Consumer Discretionary

    $AMN
    $AORT
    $CDIO
    $HCTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:51:45 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:47:09 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    3/5/25 4:01:01 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AMN
    $AORT
    $CDIO
    $HCTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Inventiva with a new price target

    Barclays initiated coverage of Inventiva with a rating of Overweight and set a new price target of $18.00

    1/28/26 7:17:30 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Inventiva with a new price target

    Leerink Partners initiated coverage of Inventiva with a rating of Outperform and set a new price target of $12.00

    1/12/26 8:13:43 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMN
    $AORT
    $CDIO
    $HCTI
    SEC Filings

    View All

    SEC Form 144 filed by Artivion Inc.

    144 - ARTIVION, INC. (0000784199) (Subject)

    2/24/26 5:05:05 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Artivion Inc.

    144 - ARTIVION, INC. (0000784199) (Subject)

    2/23/26 4:52:39 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Artivion Inc.

    144 - ARTIVION, INC. (0000784199) (Subject)

    2/23/26 4:48:48 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AMN
    $AORT
    $CDIO
    $HCTI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMN
    $AORT
    $CDIO
    $HCTI
    Leadership Updates

    Live Leadership Updates

    View All

    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

    LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Breder, MD, PhD, is a distinguished physician-scientist and regulatory expert with over two decades of experience across the U.S. Food and Drug Administration (FDA) and major pharmaceutical compa

    11/18/25 6:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Appoints Andrew Obenshain as Chief Executive Officer

    Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Andrew Obenshain as Chief Executive Officer ("CEO") of the Company. Mr. Obenshain will also join the Company's Board of Directors. He succeeds Frédéric Cren, the Company's co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth tr

    10/1/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    $AMN
    $AORT
    $CDIO
    $HCTI
    Financials

    Live finance-specific insights

    View All

    UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results

    Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(8%)Gross profit$195.1(11%)$774.1(16%)Net income (loss)($7.7)nm($95.7)nmDiluted earnings (loss) per share($0.20)nm($2.48)nmAdjusted diluted EPS*$0.22(70%)$1.36(59%)Adjusted EBITDA*$

    2/19/26 8:13:45 PM ET
    $AMN
    Professional Services
    Consumer Discretionary

    AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results

    Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(8%)Gross profit$195.1(11%)$774.1(16%)Net income (loss)($7.7)nm($95.7)nmDiluted earnings (loss) per share($0.20)nm($2.48)nmAdjusted diluted EPS*$0.22(70%)$1.36(59%)Adjusted EBITDA*$

    2/19/26 4:15:00 PM ET
    $AMN
    Professional Services
    Consumer Discretionary

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AMN
    $AORT
    $CDIO
    $HCTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ikena Oncology Inc.

    SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

    11/14/24 5:05:17 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    11/14/24 4:07:59 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/14/24 3:38:45 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care